Blocking the function of ErbB2 leads to inhibition of proliferation of cancer cells as demonstrated in preclinical (Hudziak et al, 1989; Fendly et al, 1990) and clinical studies (Baselga et al, 1996; Slamon and Pegram, 2001). This evidence concerns the gene ERBB2 and cancer.